- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03719092
High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant
Single, High Dose Vitamin A Replacement in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To assess the feasibility and safety of pre-transplant single, high dose vitamin A supplementation in adult allogeneic stem cell transplant recipients until day +28 after transplant.
OUTLINE: This is a dose-escalation study.
Participants receive vitamin A compound orally (PO) or enterally once prior to stem cell transplant.
After completion of study treatment, participants are followed up periodically.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rachel Dalton
- Email: Rachel.Dalton@osumc.edu
Study Contact Backup
- Name: Ohio State University Comprehensive Cancer Center
- Phone Number: 800-293-5066
- Email: OSUCCCClinicaltrials@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Principal Investigator:
- Hannah Choe, MD
-
Contact:
- Hannah Choe, MD
- Phone Number: 614-293-5428
- Email: Hannah.Choe@osumc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients planned to undergo an allogeneic stem cell transplant (SCT) with an human leukocyte antigen (HLA)-matched (unrelated or related) or 1 allele mismatched (7/8) donor or haploidentical donor who received either myeloablative or nonmyeloablative conditioning for hematologic malignancies are eligible
Exclusion Criteria:
- Vitamin A hypersensitivity or allergy
- Baseline pre-transplant Vitamin A levels higher than the upper quartile of normal range for age
- Abnormal liver enzymes outside of the institutional laboratory normal range within 30 days of screening
- Abnormal total, indirect, or direct bilirubin outside of the institutional laboratory normal range within 30 days of screening
- Enteral feeding intolerance
- Medication intolerance
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prevention (vitamin A compound)
Participants receive vitamin A compound PO or enterally once prior to stem cell transplant. once over a given 24 hour period with or without food. We will re-dose at 2000 IU/kg (maximum 120,000 IU) if Week 2 Vitamin A levels remain within 10% of baseline Vitamin A. |
Given PO or enterally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vitamin A dose that achieves level in the upper quartile of normal range for sex in at least 2/3 cases without dose limiting toxicity
Time Frame: Up to day 28
|
Determining a Vitamin A dose administered within 14 days prior to transplant that maintains level in the upper quartile of normal range for sex at day 28 (+/- 7 days) after stem cell infusion as well as tolerable in adult allogeneic stem cell transplant recipients. determining a Vitamin A dose administered within 14 days prior to transplant that maintains level in the upper quartile of normal range for sex at day 28 (+/- 7 days) after stem cell infusion as well as tolerable in adult allogeneic stem cell transplant recipients. |
Up to day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of gastrointestinal graft versus host disease
Time Frame: Up to day 180 after stem cell transplant
|
Cumulative incidence of GI GVHD will be calculated and graphed.
|
Up to day 180 after stem cell transplant
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hannah Choe, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-18078
- NCI-2018-01838 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allogeneic Hematopoietic Stem Cell Transplantation Recipient
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)TerminatedALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONUnited States
-
Sumithira VasuRecruitingCytomegalovirus | Adenovirus | Donor | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Solid Organ Transplantation RecipientUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient | DonorUnited States
-
Central Hospital, Nancy, FranceRecruitingAllogeneic Hematopoietic Stem Cell TransplantationFrance
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAllogeneic Hematopoietic Stem Cell TransplantationUnited States
-
Cairo UniversityCompletedAllogeneic Hematopoietic Stem Cell TransplantationEgypt
-
Universitätsklinikum Hamburg-EppendorfStaburo GmbH; Deutsche José Carreras Leukämie-StiftungUnknownAllogeneic Hematopoietic Stem Cell TransplantationGermany
-
Fujian Medical UniversityRecruitingAllogeneic Hematopoietic Stem Cell TransplantationChina
Clinical Trials on Vitamin A Compound
-
Meng QiuRecruitingMucositis | Chemotherapeutic ToxicityChina
-
Dalin Tzu Chi General HospitalRecruitingTinnitus | Sleep DisturbancesTaiwan
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedNon Small Cell Lung Cancer | Stage Ib Lung Carcinoma | Stage IIA Lung Carcinoma | Stage IIIA Lung Carcinoma | Stage I Lung Cancer | Stage IA Lung Carcinoma AJCC V7United States
-
The University of Texas Health Science Center,...CompletedHuman Papilloma Virus | Dysplasia | CIN1 | CIN2United States
-
Chinese Society of HematologyHarbin Institute of Hematology & OncologyUnknownMyelodysplastic Syndrome (MDS)
-
Meng QiuRecruitingMucositis | Chemotherapeutic ToxicityChina
-
Institut de Recherche pour le DeveloppementUniversity of Copenhagen; Thrasher Research Fund; National Institute of Nutrition...CompletedMaking Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and InflammationHealthy Women Giving Birth to Singleton InfantsVietnam
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, GermanyActive, not recruitingSoft-tissue SarcomaUnited Kingdom
-
Arafat TfayliMerck KGaA, Darmstadt, Germany; Phoenix Clinical ResearchUnknownNon-Small Cell Lung Cancer StageLebanon, Jordan